CN100463921C - 白蛋白纯化 - Google Patents
白蛋白纯化 Download PDFInfo
- Publication number
- CN100463921C CN100463921C CNB031235026A CN03123502A CN100463921C CN 100463921 C CN100463921 C CN 100463921C CN B031235026 A CNB031235026 A CN B031235026A CN 03123502 A CN03123502 A CN 03123502A CN 100463921 C CN100463921 C CN 100463921C
- Authority
- CN
- China
- Prior art keywords
- medium
- aglucon
- fermented liquid
- rhsa
- hydrophobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 15
- 108010088751 Albumins Proteins 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 56
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000006228 supernatant Substances 0.000 claims abstract description 25
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 12
- 230000002829 reductive effect Effects 0.000 claims abstract description 9
- 238000011210 chromatographic step Methods 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 58
- 230000005611 electricity Effects 0.000 claims description 12
- 125000000129 anionic group Chemical group 0.000 claims description 11
- 238000005341 cation exchange Methods 0.000 claims description 9
- 239000003292 glue Substances 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000005571 anion exchange chromatography Methods 0.000 claims description 5
- 239000012501 chromatography medium Substances 0.000 claims description 5
- 238000005277 cation exchange chromatography Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000002086 displacement chromatography Methods 0.000 claims 4
- 230000001588 bifunctional effect Effects 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 abstract description 12
- -1 salt cation Chemical class 0.000 abstract description 11
- 238000000746 purification Methods 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 29
- 239000011159 matrix material Substances 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- 238000013016 damping Methods 0.000 description 12
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 229920002684 Sepharose Polymers 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 8
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 6
- 239000012619 Butyl Sepharose® Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 229920002271 DEAE-Sepharose Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 239000011147 inorganic material Substances 0.000 description 4
- 239000011368 organic material Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 150000003009 phosphonic acids Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229910001936 tantalum oxide Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201518A SE526227C2 (sv) | 2002-05-15 | 2002-05-15 | Metod för rening av rekombinant humant serumalbumin |
| SE02015188 | 2002-05-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1496993A CN1496993A (zh) | 2004-05-19 |
| CN100463921C true CN100463921C (zh) | 2009-02-25 |
Family
ID=20287916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031235026A Expired - Fee Related CN100463921C (zh) | 2002-05-15 | 2003-05-09 | 白蛋白纯化 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7423124B2 (https=) |
| EP (2) | EP1504031B1 (https=) |
| JP (2) | JP2006502098A (https=) |
| CN (1) | CN100463921C (https=) |
| AT (1) | ATE335006T1 (https=) |
| AU (2) | AU2003228193B2 (https=) |
| BR (2) | BRPI0309992B1 (https=) |
| CA (2) | CA2483612A1 (https=) |
| DE (1) | DE60307262T2 (https=) |
| ES (1) | ES2268362T3 (https=) |
| IL (1) | IL164844A (https=) |
| SE (1) | SE526227C2 (https=) |
| WO (2) | WO2003097692A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802146B2 (en) * | 1998-11-06 | 2014-08-12 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
| SI1599463T1 (sl) * | 2003-01-28 | 2013-10-30 | E.I. Du Pont De Nemours And Company | Ciano antranilamidni insekticidi |
| CA2514981A1 (en) * | 2003-03-12 | 2004-09-23 | Fresenius Kabi Deutschland Gmbh | Use of recombinant albumin in dialysis after liver failure |
| DK2100904T3 (da) * | 2004-04-23 | 2010-11-08 | Conjuchem Biotechnologies Inc | Fast fase til anvendelse i en fremgangsmåde til rensning af albuminkonjugater |
| CN1854155B (zh) * | 2005-04-29 | 2010-11-17 | 华北制药集团新药研究开发有限责任公司 | 一种纯化rHSA的方法 |
| CL2008002054A1 (es) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| CN101978268B (zh) * | 2008-03-31 | 2014-04-23 | 积水医疗株式会社 | 纯化血清白蛋白及免疫学测定方法 |
| US8753868B2 (en) | 2008-08-04 | 2014-06-17 | General Electric Company | Method and system for selective isolation of target biological molecules in a general purpose system |
| CN101768206B (zh) * | 2008-12-31 | 2013-05-15 | 华北制药集团新药研究开发有限责任公司 | 一种重组人血清白蛋白的纯化方法及其应用 |
| CA2752729A1 (en) | 2009-02-20 | 2010-08-26 | Ventria Bioscience | Cell culture media containing combinations of proteins |
| EP4492053A3 (en) * | 2010-05-25 | 2025-03-19 | F. Hoffmann-La Roche AG | Methods of purifying polypeptides |
| CN102127164B (zh) | 2010-12-20 | 2013-01-30 | 武汉禾元生物科技有限公司 | 一种从水稻种子中提取重组人血清白蛋白的方法 |
| CN102532254B (zh) * | 2010-12-24 | 2015-06-24 | 武汉禾元生物科技股份有限公司 | 一种从水稻种子中分离纯化重组人血清白蛋白的方法 |
| CN104812491B (zh) * | 2012-03-08 | 2018-06-19 | 生物辐射实验室股份有限公司 | 阴离子交换-疏水性混合模式 |
| CN103880947B (zh) | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | 一种分离纯化高纯度重组人血清白蛋白的层析方法 |
| CN103923211A (zh) * | 2014-05-08 | 2014-07-16 | 齐智 | 一种医药级重组人血清白蛋白的纯化方法 |
| EP4424326A3 (en) | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| CN106117326A (zh) * | 2015-12-09 | 2016-11-16 | 烟台大学 | 一种离心法结合阴离子交换层析介质制备藻红蛋白的方法 |
| CN106146631A (zh) * | 2015-12-09 | 2016-11-23 | 烟台大学 | 一种离心技术结合疏水层析介质制备藻红蛋白的方法 |
| CN106117347A (zh) * | 2015-12-09 | 2016-11-16 | 烟台大学 | 一种疏水层析制备高纯度藻红蛋白的方法 |
| EP4653865A3 (en) | 2019-09-24 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| US12161777B2 (en) | 2020-07-02 | 2024-12-10 | Davol Inc. | Flowable hemostatic suspension |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| WO2022120547A1 (zh) | 2020-12-08 | 2022-06-16 | 通化安睿特生物制药股份有限公司 | 纯化重组蛋白的方法 |
| EP4267210A1 (en) | 2020-12-28 | 2023-11-01 | Davol Inc. | Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent |
| CN113461804A (zh) * | 2021-08-09 | 2021-10-01 | 山东健通生物科技有限公司 | 减少重组人血白蛋白发酵过程中色素的方法 |
| CN113880908B (zh) * | 2021-08-25 | 2024-05-14 | 北京伟德杰生物科技有限公司 | 纯化重组人血清白蛋白的融合蛋白的方法 |
| CN113735962B (zh) * | 2021-08-27 | 2023-11-10 | 常熟纳微生物科技有限公司 | 一种从猪血中纯化重组人血清白蛋白的方法及应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5986062A (en) * | 1992-05-20 | 1999-11-16 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093612A (en) * | 1975-08-04 | 1978-06-06 | Research Corporation | Selective removal of albumin from blood fluids and compositions therefore |
| FR2403098A1 (fr) * | 1977-09-19 | 1979-04-13 | Merieux Inst | Nouveau materiau capable de fixer de facon reversible des macromolecules biologiques, sa preparation et son application |
| US5849874A (en) * | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| DE69230273T2 (de) * | 1991-07-12 | 2000-05-31 | Dsm N.V., Heerlen | Verfahren zur Reinigung von Serumalbumin |
| JPH07102148B2 (ja) * | 1992-05-20 | 1995-11-08 | 株式会社ミドリ十字 | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| CA2116385A1 (en) * | 1993-02-25 | 1994-08-26 | Akinori Sumi | Human serum albumin and process for producing the same |
| CA2138349A1 (en) * | 1993-12-17 | 1995-06-18 | Welfide Corporation | Method for decoloring human serum albumin |
| CA2157219C (en) | 1994-08-31 | 2010-10-05 | Munehiro Noda | Process for purifying recombinant human serum albumin |
| JP3840674B2 (ja) * | 1994-08-31 | 2006-11-01 | 三菱ウェルファーマ株式会社 | 遺伝子操作に由来するヒト血清アルブミンの精製方法 |
| GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| SE0002688D0 (sv) | 2000-07-17 | 2000-07-17 | Amersham Pharm Biotech Ab | Adsorption method and ligands |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
-
2002
- 2002-05-15 SE SE0201518A patent/SE526227C2/sv not_active IP Right Cessation
-
2003
- 2003-05-09 US US10/514,536 patent/US7423124B2/en not_active Expired - Lifetime
- 2003-05-09 ES ES03725953T patent/ES2268362T3/es not_active Expired - Lifetime
- 2003-05-09 BR BRPI0309992-0A patent/BRPI0309992B1/pt active IP Right Grant
- 2003-05-09 EP EP03725953A patent/EP1504031B1/en not_active Expired - Lifetime
- 2003-05-09 WO PCT/SE2003/000766 patent/WO2003097692A1/en not_active Ceased
- 2003-05-09 JP JP2004506364A patent/JP2006502098A/ja active Pending
- 2003-05-09 CN CNB031235026A patent/CN100463921C/zh not_active Expired - Fee Related
- 2003-05-09 BR BRPI0309992A patent/BRPI0309992B8/pt active IP Right Grant
- 2003-05-09 CA CA002483612A patent/CA2483612A1/en not_active Abandoned
- 2003-05-09 AT AT03725953T patent/ATE335006T1/de not_active IP Right Cessation
- 2003-05-09 DE DE60307262T patent/DE60307262T2/de not_active Expired - Lifetime
- 2003-05-09 AU AU2003228193A patent/AU2003228193B2/en not_active Ceased
- 2003-05-15 AU AU2003232704A patent/AU2003232704A1/en not_active Abandoned
- 2003-05-15 CA CA002483616A patent/CA2483616A1/en not_active Abandoned
- 2003-05-15 EP EP03752962A patent/EP1504032A1/en not_active Withdrawn
- 2003-05-15 US US10/514,544 patent/US7351801B2/en not_active Expired - Fee Related
- 2003-05-15 WO PCT/SE2003/000792 patent/WO2003097693A1/en not_active Ceased
- 2003-05-15 JP JP2004506365A patent/JP4559216B2/ja not_active Expired - Fee Related
-
2004
- 2004-10-26 IL IL164844A patent/IL164844A/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5986062A (en) * | 1992-05-20 | 1999-11-16 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0309992B8 (pt) | 2023-03-21 |
| AU2003228193A1 (en) | 2003-12-02 |
| EP1504032A1 (en) | 2005-02-09 |
| ATE335006T1 (de) | 2006-08-15 |
| DE60307262D1 (de) | 2006-09-14 |
| SE0201518D0 (sv) | 2002-05-15 |
| JP4559216B2 (ja) | 2010-10-06 |
| JP2006502098A (ja) | 2006-01-19 |
| US20050214902A1 (en) | 2005-09-29 |
| WO2003097693A1 (en) | 2003-11-27 |
| BRPI0309992B1 (pt) | 2020-12-22 |
| ES2268362T3 (es) | 2007-03-16 |
| CA2483616A1 (en) | 2003-11-27 |
| BR0309992A (pt) | 2005-03-01 |
| AU2003228193B2 (en) | 2009-05-07 |
| JP2006512283A (ja) | 2006-04-13 |
| US7423124B2 (en) | 2008-09-09 |
| US7351801B2 (en) | 2008-04-01 |
| DE60307262T2 (de) | 2007-06-28 |
| IL164844A (en) | 2009-09-01 |
| IL164844A0 (en) | 2005-12-18 |
| SE526227C2 (sv) | 2005-08-02 |
| WO2003097692A1 (en) | 2003-11-27 |
| EP1504031B1 (en) | 2006-08-02 |
| US20050215765A1 (en) | 2005-09-29 |
| AU2003232704A1 (en) | 2003-12-02 |
| EP1504031A1 (en) | 2005-02-09 |
| CA2483612A1 (en) | 2003-11-27 |
| CN1496993A (zh) | 2004-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100463921C (zh) | 白蛋白纯化 | |
| CA2157219A1 (en) | Process for purifying recombinant human serum albumin | |
| IE44507B1 (en) | Cationic material capable of reversibly fixing biological macromolecules | |
| US5234991A (en) | Porous mineral support coated with an aminated polysaccharide polymer | |
| RU2007132851A (ru) | Способ мягкой распределительной хроматографии | |
| CN101260145B (zh) | 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺 | |
| Safarik et al. | Magnetic cation exchange isolation of lysozyme from native hen egg white | |
| KR920009730B1 (ko) | 백일해 성분 백신 및 백일해 항원, 디프테리아 톡소이드 및 파상풍 톡소이드의 혼합백신의 제조방법 | |
| US6177548B1 (en) | Enhanced aggregate removal from bulk biologicals using ion exchange chromatography | |
| Wakefield et al. | Isolation of a membrane protein by chromatofocusing: cytochrome b-561 of the adrenal chromaffin granule | |
| US6555661B1 (en) | Simple, environmentally benign, method for purifying protein A | |
| CN101250512B (zh) | 内切木聚糖酶的仿生亲和纯化方法 | |
| Penner et al. | Fumarase: demonstration, separation, and hybridization of different subunit types | |
| CN111871396A (zh) | 一种白蛋白静电亲和双模式层析介质及其制备方法和应用 | |
| WO1995029187A1 (en) | Chromatographic process for the copurification of chondroitinase i and ii proteins | |
| KR890001069B1 (ko) | B형 간염 항원의 정제방법 | |
| Scott et al. | Affinity chromatography purification of Clostridium perfringens enterotoxin | |
| EP0868507B1 (en) | Process for the purification of urease from helicobacter pylori | |
| RU2036236C1 (ru) | Способ очистки щелочной фосфатазы из тонкого кишечника тюленя | |
| Laursen et al. | Extending the performance of the solid-phase protein sequencer | |
| CN119709869A (zh) | 一种腺相关病毒载体的纯化方法 | |
| KR20050016877A (ko) | 알부민 정제 방법 | |
| JPS59169490A (ja) | 酸性プロテア−ゼの採取法 | |
| JPS60243025A (ja) | コレラトキシンサブユニツトｂの製造法 | |
| CN1276425A (zh) | 一种提纯葡萄糖氧化酶的方法和装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090225 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |